Igor S. Bazin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Igor S. Bazin has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandr N. Polyakov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
10 shared publications - Danila V. Podluzhnyi
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
7 shared publications - Alexey A. Tryakin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
6 shared publications - Mariam Manukyan
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
6 shared publications - Yurii I. Patyutko
N.N. Blokhin National Medical Research Center of Oncology оf the Ministry of Health of the Russian Federation
6 shared publications - D. M. Kantieva
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (2) , 65-75
Systematic review of the role of surgery in the treatment of pancreatic cancer with liver oligometastases
Pancreatic cancer remains one of the most aggressive malignancies with an extremely poor prognosis. Despite advances in systemic therapy five-year survival rates for patients with disseminated forms of the disease still do not exceed a few percent. Surgical treatment for advanced pancreatic cancer is not performed in routine practice and is considered palliative.However, efforts to introduce surgery for stage IV disease continue to be investigated particularly in patients with oligometastatic disease. This group of patients occupies an intermediate position in terms of tumor biology between localized cancer and disseminated disease, providing a theoretical rationale for the use of radical local treatment modalities in combination with effective systemic therapy.The aim of this review is to systematize current data regarding the role efficacy and safety of surgical treatment in patients with oligometastatic pancreatic cancer as well as to define the selection criteria for patients most suitable for combined treatment. This work analyzes the results of key studies and discusses prognostic factors that enable the selection of the most appropriate candidates for combined treatment.
- 28 August 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (2) , 65-75
Open AccessSystematic review of the role of surgery in the treatment of pancreatic cancer with liver oligometastases
Pancreatic cancer remains one of the most aggressive malignancies with an extremely poor prognosis. Despite advances in systemic therapy five-year survival rates for patients with disseminated forms of the disease still do not exceed a few percent. Surgical treatment for advanced pancreatic cancer is not performed in routine practice and is considered palliative.However, efforts to introduce surgery for stage IV disease continue to be investigated particularly in patients with oligometastatic disease. This group of patients occupies an intermediate position in terms of tumor biology between localized cancer and disseminated disease, providing a theoretical rationale for the use of radical local treatment modalities in combination with effective systemic therapy.The aim of this review is to systematize current data regarding the role efficacy and safety of surgical treatment in patients with oligometastatic pancreatic cancer as well as to define the selection criteria for patients most suitable for combined treatment. This work analyzes the results of key studies and discusses prognostic factors that enable the selection of the most appropriate candidates for combined treatment.
- Open Access
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 99-106
Comparison of efficacy and tolerability of gemcitabine and gemcitabine plus nab-paclitaxel in 2nd line therapy for pancreatic cancer. Experience of one center
Background. First-line therapy for advanced pancreatic cancer often involves combination regimens, including gemcitabine plus nab-paclitaxel (GEM-NAB), whereas the optimal treatment strategy in the second-line setting remains a subject of debate. Aim. To compare efficacy and tolerability of gemcitabine (GEM) monotherapy and GEM-NAB combination as second-line treatment for pancreatic cancer. Materials and methods. This retrospective single-center study was conducted in patients with pancreatic adenocarcinoma receiving second-line chemotherapy with one of two regimens: GEM monotherapy or the GEM-NAB combination. The primary endpoint was overall survival. Secondary endpoints included progression-free survival, objective response rate, disease control rate, and safety. Results. A total of 118 patients were included: 57 received GEM and 61 received GEM-NAB. The groups were comparable in baseline clinical and demographic characteristics. Median follow-up was 9 months. Median OS was 5.9 months (95 % confidence interval (CI) 3.8–8.0) in the GEM group and 6.4 months (95 % CI 4.5–8.3) in the GEM-NAB group (p = 0.772). Median progression-free survival was 3.3 months (95 % CI 2.8–3.8) and 4.7 months (95 % CI 3.6–5.8), respectively (p = 0.079). Objective response rate was 15.8 % and 28.6 %, respectively (p = 0.127). The incidence of grade III–IV adverse events was comparable between the groups. In multivariate analysis, ECOG status ≥ 2, liver metastases, and decreased hemoglobin level were identified as independent predictors of poor survival. Conclusion. Gemcitabine plus nab-paclitaxel combination as 2nd line therapy did not demonstrate statistically significant improvement in overall survival compared with gemcitabine monotherapy and showed a comparable safety profile.
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 99-106
Open AccessComparison of efficacy and tolerability of gemcitabine and gemcitabine plus nab-paclitaxel in 2nd line therapy for pancreatic cancer. Experience of one center
Background. First-line therapy for advanced pancreatic cancer often involves combination regimens, including gemcitabine plus nab-paclitaxel (GEM-NAB), whereas the optimal treatment strategy in the second-line setting remains a subject of debate. Aim. To compare efficacy and tolerability of gemcitabine (GEM) monotherapy and GEM-NAB combination as second-line treatment for pancreatic cancer. Materials and methods. This retrospective single-center study was conducted in patients with pancreatic adenocarcinoma receiving second-line chemotherapy with one of two regimens: GEM monotherapy or the GEM-NAB combination. The primary endpoint was overall survival. Secondary endpoints included progression-free survival, objective response rate, disease control rate, and safety. Results. A total of 118 patients were included: 57 received GEM and 61 received GEM-NAB. The groups were comparable in baseline clinical and demographic characteristics. Median follow-up was 9 months. Median OS was 5.9 months (95 % confidence interval (CI) 3.8–8.0) in the GEM group and 6.4 months (95 % CI 4.5–8.3) in the GEM-NAB group (p = 0.772). Median progression-free survival was 3.3 months (95 % CI 2.8–3.8) and 4.7 months (95 % CI 3.6–5.8), respectively (p = 0.079). Objective response rate was 15.8 % and 28.6 %, respectively (p = 0.127). The incidence of grade III–IV adverse events was comparable between the groups. In multivariate analysis, ECOG status ≥ 2, liver metastases, and decreased hemoglobin level were identified as independent predictors of poor survival. Conclusion. Gemcitabine plus nab-paclitaxel combination as 2nd line therapy did not demonstrate statistically significant improvement in overall survival compared with gemcitabine monotherapy and showed a comparable safety profile.
- 4 June 2026
- Published by Alfmed LLC in Medical alphabet
- No. 8
Efficacy of mFOLFIRINOX reinduction in locally advanced unresectable and metastatic pancreatic cancer in real clinical practice
Pancreatic cancer remains one of the most aggressive malignancies with an unfavorable prognosis. Over 50 % of patients present with distant metastases at initial diagnosis and the five-year overall survival in this cohort does not exceed 3 % [1, 2]. In contemporary clinical practice the combination regimens mFOLFIRINOX and GemNab have become firmly established as first-line therapy standards in both Russian (RUSSCO) and international (ESMO, NCCN) clinical guidelines [3, 4, 5]. However determining the optimal therapeutic approach upon disease progression remains challenging due to limited evidence-based options highlighting the need to explore new treatment strategies including the reinduction of previously used regimens. A single-center retrospective study conducted at the N. N. Blokhin National Medical Research Center of Oncology analyzed data from 31 patients with locally advanced or metastatic pancreatic adenocarcinoma who received mFOLFIRINOX reinduction following a progression-free interval of at least 3 months after first-line chemotherapy. The study assessed progression-free survival during first-line therapy (PFS 1) and reinduction (PFS 2), as well as overall survival from diagnosis (OS) and from reinduction initiation (OS 2). Median PFS 1 was 13 months (95 % CI: 11.6–14.4), and median PFS 2 was 7.0 months (95 % CI: 5.7–8.3). Median OS reached 23.0 months (95 % CI: 18.5–27.5), while median OS 2 was 8.0 months (95 % CI: 6.2–9.8). The toxicity profile upon retreatment was comparable to initial treatment with a trend toward reduced hematologic toxicity likely associated with optimized supportive care. In conclusion the preliminary data from our study demonstrate that the mFOLFIRINOX reintroduction strategy is a promising approach in the treatment of patients with locally advanced and metastatic pancreatic cancer. The results indicate clinically meaningful efficacy of regimen reuse, warranting further investigation of this approach.
- 4 June 2026
- Published by Alfmed LLC in Medical alphabet
- No. 8
Efficacy of mFOLFIRINOX reinduction in locally advanced unresectable and metastatic pancreatic cancer in real clinical practice
Pancreatic cancer remains one of the most aggressive malignancies with an unfavorable prognosis. Over 50 % of patients present with distant metastases at initial diagnosis and the five-year overall survival in this cohort does not exceed 3 % [1, 2]. In contemporary clinical practice the combination regimens mFOLFIRINOX and GemNab have become firmly established as first-line therapy standards in both Russian (RUSSCO) and international (ESMO, NCCN) clinical guidelines [3, 4, 5]. However determining the optimal therapeutic approach upon disease progression remains challenging due to limited evidence-based options highlighting the need to explore new treatment strategies including the reinduction of previously used regimens. A single-center retrospective study conducted at the N. N. Blokhin National Medical Research Center of Oncology analyzed data from 31 patients with locally advanced or metastatic pancreatic adenocarcinoma who received mFOLFIRINOX reinduction following a progression-free interval of at least 3 months after first-line chemotherapy. The study assessed progression-free survival during first-line therapy (PFS 1) and reinduction (PFS 2), as well as overall survival from diagnosis (OS) and from reinduction initiation (OS 2). Median PFS 1 was 13 months (95 % CI: 11.6–14.4), and median PFS 2 was 7.0 months (95 % CI: 5.7–8.3). Median OS reached 23.0 months (95 % CI: 18.5–27.5), while median OS 2 was 8.0 months (95 % CI: 6.2–9.8). The toxicity profile upon retreatment was comparable to initial treatment with a trend toward reduced hematologic toxicity likely associated with optimized supportive care. In conclusion the preliminary data from our study demonstrate that the mFOLFIRINOX reintroduction strategy is a promising approach in the treatment of patients with locally advanced and metastatic pancreatic cancer. The results indicate clinically meaningful efficacy of regimen reuse, warranting further investigation of this approach.
- 19 December 2025
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 12,p. 69-79
Postoperative outcomes and role of adjuvant therapy in common bile duct cancer
Objective. To determine prognostic factors in resectable common bile duct (CBD) cancer and feasibility of adjuvant therapy. Material and methods. We retrospectively studied the results of pancreatoduodenectomy for CBD cancer in 1999—2023. Results. There were 89 patients, mortality rate was 5.6% (n=5), complications developed in 66 patients (74.2%), complications ≥ grade III — in 37 (41.7%) cases. Postoperative pancreatic fistula (POPF) grade B/C was detected in 29 (32.6%) cases. Postoperative chemotherapy was administered to 43 patients (gemcitabine-based therapy — 27, capecitabine alone — 15, capecitabine/oxaliplatin combination — 1). The median overall survival was 33 months, disease-free survival — 19 months. Among patients selected for assessment of long-term results (n=79), the median OS was 37 months, DFS — 30 months. Retroperitoneal invasion (RPI), pancreatic invasion (PI), perineural invasion (PNI), moderate/poor differentiation, R1 resection, retroperitoneal lymph node (LN) involvement worsened long-term results in multivariate analysis, regional LN involvement and elevated CA 19-9 — in univariate analysis. Accumulation of factors worsened prognosis. Postoperative chemotherapy improved OS (median OS 35 months vs. 16.5, p=0.035) in patients with two or more negative prognostic factors. Chemotherapy mode did not affect prognosis. Conclusion. Retroperitoneal, pancreatic and perineural invasion, R1 resection, moderate/poor tumor differentiation, lymph node involvement and elevated CA 19-9 are negative prognostic factors in CBD cancer. Postoperative capecitabine monotherapy is justified in patients with two or more negative factors.
- 19 December 2025
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 12,p. 69-79
Postoperative outcomes and role of adjuvant therapy in common bile duct cancer
Objective. To determine prognostic factors in resectable common bile duct (CBD) cancer and feasibility of adjuvant therapy. Material and methods. We retrospectively studied the results of pancreatoduodenectomy for CBD cancer in 1999—2023. Results. There were 89 patients, mortality rate was 5.6% (n=5), complications developed in 66 patients (74.2%), complications ≥ grade III — in 37 (41.7%) cases. Postoperative pancreatic fistula (POPF) grade B/C was detected in 29 (32.6%) cases. Postoperative chemotherapy was administered to 43 patients (gemcitabine-based therapy — 27, capecitabine alone — 15, capecitabine/oxaliplatin combination — 1). The median overall survival was 33 months, disease-free survival — 19 months. Among patients selected for assessment of long-term results (n=79), the median OS was 37 months, DFS — 30 months. Retroperitoneal invasion (RPI), pancreatic invasion (PI), perineural invasion (PNI), moderate/poor differentiation, R1 resection, retroperitoneal lymph node (LN) involvement worsened long-term results in multivariate analysis, regional LN involvement and elevated CA 19-9 — in univariate analysis. Accumulation of factors worsened prognosis. Postoperative chemotherapy improved OS (median OS 35 months vs. 16.5, p=0.035) in patients with two or more negative prognostic factors. Chemotherapy mode did not affect prognosis. Conclusion. Retroperitoneal, pancreatic and perineural invasion, R1 resection, moderate/poor tumor differentiation, lymph node involvement and elevated CA 19-9 are negative prognostic factors in CBD cancer. Postoperative capecitabine monotherapy is justified in patients with two or more negative factors.
- 26 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 14,p. 26-30
Combined treatment for locally advanced BRCA1-associated pancreatic cancer: a case report
Pancreatic cancer (PC) remains one of the most aggressive malignancies with poor prognosis, particularly in locally advanced and metastatic forms. Germline BRCA1/2 mutations, found in approximately 5 % of PC patients, are associated with increased sensitivity to platinum-based chemotherapy (CT) and PARP inhibitor therapy. This article presents a clinical case of successful combined treatment for locally advanced BRCA1-associated PC. The reported case demonstrates the efficacy of a comprehensive approach incorporating platinum-based CT, irreversible electroporation (IRE), pancreatic resection, stereotactic radiotherapy (RT), and PARP inhibitor targeted therapy in BRCA1-associated PC. The study highlights the crucial importance of molecular genetic testing at initial diagnosis for optimal treatment strategy selection. The findings confirm both the efficacy and safety of prolonged olaparib administration, warranting further investigation of this therapeutic approach in clinical trials.
- 26 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 14,p. 26-30
Combined treatment for locally advanced BRCA1-associated pancreatic cancer: a case report
Pancreatic cancer (PC) remains one of the most aggressive malignancies with poor prognosis, particularly in locally advanced and metastatic forms. Germline BRCA1/2 mutations, found in approximately 5 % of PC patients, are associated with increased sensitivity to platinum-based chemotherapy (CT) and PARP inhibitor therapy. This article presents a clinical case of successful combined treatment for locally advanced BRCA1-associated PC. The reported case demonstrates the efficacy of a comprehensive approach incorporating platinum-based CT, irreversible electroporation (IRE), pancreatic resection, stereotactic radiotherapy (RT), and PARP inhibitor targeted therapy in BRCA1-associated PC. The study highlights the crucial importance of molecular genetic testing at initial diagnosis for optimal treatment strategy selection. The findings confirm both the efficacy and safety of prolonged olaparib administration, warranting further investigation of this therapeutic approach in clinical trials.
- Open Access
- 20 March 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (1) , 28-35
Characteristics of KRAS gene mutations in real clinical practice for pancreatic cancer
Background. Pancreatic cancer (PC) has long been a disease with limited treatment options, where the foundation of therapy was primarily based on cytostatics. However, with the advent of the first KRAS G12C inhibitors, new prospects have emerged for the treatment of advanced PC, highlighting the importance of studying KRAS mutations, which occur in 80–95 % of cases. In this context, it is relevant to analyze the frequency of various KRAS mutations among the Russian population of patients with PC, which could help personalize further diagnostics and therapy.Aim. To study the features of KRAS status in patients younger and older than 65 years with pancreatic adenocarcinoma in real clinical practice.Materials and methods. We retrospectively analyzed the data of 590 patients with pancreatic adenocarcinoma who underwent molecular genetic research and treatment at the N. N. Blokhin from 2022 to 2024. Patients with primary multiple malignancies were excluded from the study. Inclusion criteria were the presence of histological verification of the diagnosis and known KRAS, NRAS, BRCA 1/2, CHEK2, PALB2, ATM status. Patients were divided into two age groups, younger and older than 65 years. The primary endpoint was a comparative assessment of the mutation rate in both groups.Results. 129 patients were included in the analysis. The detection rate of wild-type KRAS in the general population was 24.8 %. The most common mutations in both age groups were p.G12V and p.G12D, accounting for 79.2 % of all mutations in the KRAS gene. The p.G12C mutation was detected in two patients (2 %). Five clinically significant mutations in the BRCA 1/2 genes were identified; the patient with mBRCA1 had a wild type KRAS gene. The remaining 4 patients with a BRCA2 mutation also had a KRAS mutation.Conclusion. Given the increasing number of drugs that affect KRAS and the ability to detect other alterations in wtKRAS, integration of KRAS testing into routine practice in the evaluation of patients with pancreatic adenocarcinoma is necessary.
- 20 March 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (1) , 28-35
Open AccessCharacteristics of KRAS gene mutations in real clinical practice for pancreatic cancer
Background. Pancreatic cancer (PC) has long been a disease with limited treatment options, where the foundation of therapy was primarily based on cytostatics. However, with the advent of the first KRAS G12C inhibitors, new prospects have emerged for the treatment of advanced PC, highlighting the importance of studying KRAS mutations, which occur in 80–95 % of cases. In this context, it is relevant to analyze the frequency of various KRAS mutations among the Russian population of patients with PC, which could help personalize further diagnostics and therapy.Aim. To study the features of KRAS status in patients younger and older than 65 years with pancreatic adenocarcinoma in real clinical practice.Materials and methods. We retrospectively analyzed the data of 590 patients with pancreatic adenocarcinoma who underwent molecular genetic research and treatment at the N. N. Blokhin from 2022 to 2024. Patients with primary multiple malignancies were excluded from the study. Inclusion criteria were the presence of histological verification of the diagnosis and known KRAS, NRAS, BRCA 1/2, CHEK2, PALB2, ATM status. Patients were divided into two age groups, younger and older than 65 years. The primary endpoint was a comparative assessment of the mutation rate in both groups.Results. 129 patients were included in the analysis. The detection rate of wild-type KRAS in the general population was 24.8 %. The most common mutations in both age groups were p.G12V and p.G12D, accounting for 79.2 % of all mutations in the KRAS gene. The p.G12C mutation was detected in two patients (2 %). Five clinically significant mutations in the BRCA 1/2 genes were identified; the patient with mBRCA1 had a wild type KRAS gene. The remaining 4 patients with a BRCA2 mutation also had a KRAS mutation.Conclusion. Given the increasing number of drugs that affect KRAS and the ability to detect other alterations in wtKRAS, integration of KRAS testing into routine practice in the evaluation of patients with pancreatic adenocarcinoma is necessary.
- 18 February 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (2) , 358-366
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer
- 18 February 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (2) , 358-366
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer
- 4 February 2025
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 1,p. 5-13
Prognostic factors and preoperative therapy in resectable intrahepatic cholangiocarcinoma
Objective. To identify prognostic factors and role of preoperative therapy for resectable intrahepatic cholangiocarcinoma (IHCC). Material and methods. We analyzed the results of surgical and combined treatment of IHCC between 1999 and 2023. Immediate and long-term outcomes were evaluated depending on negative prognostic factors and additional therapy. Results. The study included 195 patients. Postoperative complications grade ≥III were observed in 35 (17.9%) case. Mortality rate was 3.1% (n=6). Thirty-eight patients (19.5%) underwent treatment before surgery, 109 (55.9%) ones — after surgery. The median overall survival was 31 months, 5-year overall survival — 32.0%. The following factors worsened overall survival: node size ≥8 cm (HR 1.45; 95% CI 0.97—2.17), invasion (HR 1.63; 95% CI 1.07—2.47), multiple lesion (HR 1.51; 95% CI 1.00—2.28). R1 resection worsened disease-free survival (HR 1.88; 95% CI 1.14—3.10). Lymph node metastases decreased overall (HR 1.96; 95% CI 1.27- 3.04) and disease-free survival (HR 2.37; 95% CI 1.63—3.44). Two and more negative factors worsened overall (p=0.0013) and disease-free survival (p=0.0005). Absence of adjuvant therapy worsened overall (HR 2.12; 95% CI 1.41—3.20) and disease-free survival (HR 1.42; 95% CI 0.99—2.04). There was a trend towards higher overall (p=0.088) and progression-free survival (p=0.029) in case of preoperative therapy (n=195). In unfavorable prognosis group, preoperative therapy (n=33) was superior to standard treatment (resection+capecitabine after surgery, n=26). There was a trend towards higher overall survival (p=0.066) and significantly better progression-free survival (17 vs 13 months, p=0.018). Conclusion. Negative prognostic factors for resectable IHCC are lesion size ≥8 cm, intrahepatic and regional metastases, invasion into neighboring structures, R1 resection. Combination of negative factors worsened prognosis. Adjuvant therapy improved postoperative outcomes. Preoperative therapy may be advisable in case of negative factors and high risk of R1 resection.
- 4 February 2025
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 1,p. 5-13
Prognostic factors and preoperative therapy in resectable intrahepatic cholangiocarcinoma
Objective. To identify prognostic factors and role of preoperative therapy for resectable intrahepatic cholangiocarcinoma (IHCC). Material and methods. We analyzed the results of surgical and combined treatment of IHCC between 1999 and 2023. Immediate and long-term outcomes were evaluated depending on negative prognostic factors and additional therapy. Results. The study included 195 patients. Postoperative complications grade ≥III were observed in 35 (17.9%) case. Mortality rate was 3.1% (n=6). Thirty-eight patients (19.5%) underwent treatment before surgery, 109 (55.9%) ones — after surgery. The median overall survival was 31 months, 5-year overall survival — 32.0%. The following factors worsened overall survival: node size ≥8 cm (HR 1.45; 95% CI 0.97—2.17), invasion (HR 1.63; 95% CI 1.07—2.47), multiple lesion (HR 1.51; 95% CI 1.00—2.28). R1 resection worsened disease-free survival (HR 1.88; 95% CI 1.14—3.10). Lymph node metastases decreased overall (HR 1.96; 95% CI 1.27- 3.04) and disease-free survival (HR 2.37; 95% CI 1.63—3.44). Two and more negative factors worsened overall (p=0.0013) and disease-free survival (p=0.0005). Absence of adjuvant therapy worsened overall (HR 2.12; 95% CI 1.41—3.20) and disease-free survival (HR 1.42; 95% CI 0.99—2.04). There was a trend towards higher overall (p=0.088) and progression-free survival (p=0.029) in case of preoperative therapy (n=195). In unfavorable prognosis group, preoperative therapy (n=33) was superior to standard treatment (resection+capecitabine after surgery, n=26). There was a trend towards higher overall survival (p=0.066) and significantly better progression-free survival (17 vs 13 months, p=0.018). Conclusion. Negative prognostic factors for resectable IHCC are lesion size ≥8 cm, intrahepatic and regional metastases, invasion into neighboring structures, R1 resection. Combination of negative factors worsened prognosis. Adjuvant therapy improved postoperative outcomes. Preoperative therapy may be advisable in case of negative factors and high risk of R1 resection.
- Open Access
- 19 December 2024
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 29 (4) , 107-114
Pancreaticoduodenectomy in multivisceral surgeries: clinical experience of two institutions
Aim. To describe the experience of multivisceral surgeries involving pancreaticoduodenectomy for tumors of various localizations, performed in two Russian medical institutions.Materials and methods. A retrospective study was conducted on the outcomes of 251 multivisceral surgeries with pancreaticoduodenectomy performed in two medical institutions from January 2011 to April 2024.Results. Tumors of pancreatic head, duodenum and large papilla of duodenum were detected in 180 cases (71.7%); colorectal tumors in 36 cases (14.3%); gastric tumors in 24 cases (9.6%); extrahepatic bile duct and gallbladder tumors in 7 cases (2.8%); renal tumors in 3 cases (1.2%); retroperitoneal tumor in 1 case (0.4%). In 107 cases, the surgery was combined with liver resection, including hemihepatectomy in 7 cases. Pancreaticoduodenectomy was combined with colorectal resection in 95 cases. Despite the extreme variability in the extent of multivisceral surgeries with pancreaticoduodenectomy, the complication rate and mortality amounted to 65.7% and 7.2%, respectively.Conclusion. The structure of multivisceral surgeries with pancreaticoduodenectomy appears to be extremely heterogeneous in terms of localization, tumor histogenesis, and the volume of surgical interventions. The frequency of postoperative complications and mortality indicates acceptable tolerability of such surgeries.
- 19 December 2024
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 29 (4) , 107-114
Open AccessPancreaticoduodenectomy in multivisceral surgeries: clinical experience of two institutions
Aim. To describe the experience of multivisceral surgeries involving pancreaticoduodenectomy for tumors of various localizations, performed in two Russian medical institutions.Materials and methods. A retrospective study was conducted on the outcomes of 251 multivisceral surgeries with pancreaticoduodenectomy performed in two medical institutions from January 2011 to April 2024.Results. Tumors of pancreatic head, duodenum and large papilla of duodenum were detected in 180 cases (71.7%); colorectal tumors in 36 cases (14.3%); gastric tumors in 24 cases (9.6%); extrahepatic bile duct and gallbladder tumors in 7 cases (2.8%); renal tumors in 3 cases (1.2%); retroperitoneal tumor in 1 case (0.4%). In 107 cases, the surgery was combined with liver resection, including hemihepatectomy in 7 cases. Pancreaticoduodenectomy was combined with colorectal resection in 95 cases. Despite the extreme variability in the extent of multivisceral surgeries with pancreaticoduodenectomy, the complication rate and mortality amounted to 65.7% and 7.2%, respectively.Conclusion. The structure of multivisceral surgeries with pancreaticoduodenectomy appears to be extremely heterogeneous in terms of localization, tumor histogenesis, and the volume of surgical interventions. The frequency of postoperative complications and mortality indicates acceptable tolerability of such surgeries.
- Open Access
- 14 November 2024
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (5) , 126-132
Pancreatic ductual carcinoma with isolated liver metastases: is it worth performing surgical resection?
Pancreatic ductal cancer is one of the most aggressive malignancy with a high incidence of advanced stages at the time of diagnosis and unsatisfactory long-term treatment results. It is believed that pancreatic ductal cancer in the presence of distant metastases identified at the stage of intraoperative revision or before surgery is a contraindication to surgical treatment. There is currently renewed interest in surgical treatment of patients with oligometastatic pancreatic cancer.Material and Methods. The search for sources was carried out in the PubMed and Elibrary systems from January 1995 to January 2024. Of the 1321 sources found, 37 were used to write the review. Data from both retrospective and prospective clinical studies that focused on the results of combined modality treatment of pancreatic cancer with isolated liver metastases were included.Results. To date, a standard treatment strategy for patients with oligometastatic pancreatic cancer has not yet been established; there are no definitive criteria for selecting patients who may benefit from surgical treatment. The current selection criteria for surgery for metastatic pancreatic cancer are far from ideal, extremely heterogeneous and, as a rule, are based only on certain clinical and instrumental data. The starting point for developing selection criteria for surgical treatment of patients with metastatic pancreatic cancer is a common understanding of what “oligometastatic pancreatic cancer” is.
- 14 November 2024
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (5) , 126-132
Open AccessPancreatic ductual carcinoma with isolated liver metastases: is it worth performing surgical resection?
Pancreatic ductal cancer is one of the most aggressive malignancy with a high incidence of advanced stages at the time of diagnosis and unsatisfactory long-term treatment results. It is believed that pancreatic ductal cancer in the presence of distant metastases identified at the stage of intraoperative revision or before surgery is a contraindication to surgical treatment. There is currently renewed interest in surgical treatment of patients with oligometastatic pancreatic cancer.Material and Methods. The search for sources was carried out in the PubMed and Elibrary systems from January 1995 to January 2024. Of the 1321 sources found, 37 were used to write the review. Data from both retrospective and prospective clinical studies that focused on the results of combined modality treatment of pancreatic cancer with isolated liver metastases were included.Results. To date, a standard treatment strategy for patients with oligometastatic pancreatic cancer has not yet been established; there are no definitive criteria for selecting patients who may benefit from surgical treatment. The current selection criteria for surgery for metastatic pancreatic cancer are far from ideal, extremely heterogeneous and, as a rule, are based only on certain clinical and instrumental data. The starting point for developing selection criteria for surgical treatment of patients with metastatic pancreatic cancer is a common understanding of what “oligometastatic pancreatic cancer” is.